3D MRI in Osteoarthritis

Oei, Edwin H.G.; Zadelhoff, Tijmen A. van; Eijgenraam, Susanne M; Klein, Stefan; Hirvasniemi, Jukka; Heijden, Rianne A. van der

doi:10.1055/s-0041-1730911

Cited by 6 publications

(1 citation statement)

References 60 publications

(76 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Magnetic materials have been widely used in magnetic resonance imaging (MRI), [ 139 ] magnetic hyperthermia treatments, [ 140 ] and other medical applications because of their capacity for deep tissue penetration and lack of detrimental ionization effects. Magnetic materials, therefore, offer a promising method for cell localization, monitoring, [ 141 ] and drug delivery [ 142 ] linked to the therapeutic processes of stem cell implantation therapy.…”

Section: Drug Delivery Nanoplatforms Responsive To External Condition...mentioning

confidence: 99%

Stimulus‐Responsive Drug Delivery Nanoplatforms for Osteoarthritis Therapy

Jiang

Zhang

2023

Small

View full text Add to dashboard Cite

Fundamentally degenerative, OA represents a considerably negative impact on the quality of life. [1,2] With an increasingly aging global population, greater numbers of OA patients are representing a clear increase in economic and societal burden. OA is primarily characterized by the degeneration or deterioration of articular cartilage. [3] More specifically, as a result of the excessive recruitment of inflammatory cells at the joint site, [4] matrix metalloproteinase (MMP) [5] and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) [6] are overexpressed during the development of OA, which leads to the destruction of the collagen II network and glycosaminoglycan (GAG). Articular cartilage dysfunction and degradation then eventually result, often presenting with permanent pathologic alterations to the entire joint.Current pharmacological treatments, (primarily focused on pain relief and antiinflammation), and/or surgery, (including microfracture surgery and joint replacement), are the most conventional therapeutic approaches for OA. [1,7] There are several disadvantages to these conventional approaches. Whilst microfracture surgery provides a measure of relief and functional recovery of the smaller-scale joint defects through the local generation of fibrocartilage from bone marrow obtained from the subchondral bone, due to the lower abrasion-resistance ability of fibrocartilage this method is often unsuitable to provide long-term relief, or for situations where large-scale defects have occurred. [8] A number of clinical strategies of joint replacement, including osteochondral autografts or allografts, are also limited by the restricted availability of donor grafts or by complications requiring secondary surgery. [9] Along with the continued development of surgical treatments, more advanced therapeutic methods have also been developed for OA surgery. These include ACI (autologous chondrocyte implantation) and MACI (matrix-induced autologous chondrocyte implantation). However, for ACI, the viability and loss of chondrocytes during the planting procedure seem to be an unavoidable problem. MACI was developed as a potential solution to this, where the in vitro use of a biodegradable (collagen matrix membrane) material as a temporary scaffold for the pre-plantation of chondrocytes could effectively lessen the loss of cells during the process of transplantation. However, for patients of more advanced ages or with too large an area of injury to the cartilage, MACI remains an unsuitable therapeutic approach.Osteoarthritis (OA) is one of the most prevalent age-related degenerative diseases. With an increasingly aging global population, greater numbers of OA patients are providing clear economic and societal burdens. Surgical and pharmacological treatments are the most common and conventional therapeutic strategies for OA, but often fall considerably short of desired or optimal outcomes. With the development of stimulus-responsive nanoplatforms has come the potential for improved therapeutic strategies for...

show abstract

Section: Drug Delivery Nanoplatforms Responsive To External Condition...mentioning

confidence: 99%

Stimulus‐Responsive Drug Delivery Nanoplatforms for Osteoarthritis Therapy

Jiang

Zhang

2023

Small

View full text Add to dashboard Cite

show abstract

Imaging of early-stage osteoarthritis: the needs and challenges for diagnosis and classification

Oei

Runhaar

2023

Skeletal Radiol

View full text Add to dashboard Cite

In an effort to boost the development of new management strategies for OA, there is currently a shift in focus towards the diagnosis and treatment of early-stage OA. It is important to distinguish diagnosis from classification of early-stage OA. Diagnosis takes place in clinical practice, whereas classification is a process to stratify participants with OA in clinical research. For both purposes, there is an important opportunity for imaging, especially with MRI. The needs and challenges differ for early-stage OA diagnosis versus classification. Although it fulfils the need of high sensitivity and specificity for making a correct diagnosis, implementation of MRI in clinical practice is challenged by long acquisition times and high costs. For classification in clinical research, more advanced MRI protocols can be applied, such as quantitative, contrast-enhanced, or hybrid techniques, as well as advanced image analysis methods including 3D morphometric assessments of joint tissues and artificial intelligence approaches. It is necessary to follow a step-wise and structured approach that comprises, technical validation, biological validation, clinical validation, qualification, and cost-effectiveness, before new imaging biomarkers can be implemented in clinical practice or clinical research.

show abstract